About us
PulsaHeart Fintech LTD is a UK based company operating in the medical bio-technologies sector.
Currently this biomedical engineering reality is developing two projects:
VAD, a ventricular cardiac device;
ARINAS, a software for cardiac valve surgical reconstruction.
Become a PulsaHeart Fintech Member
Support innovation in cardiology and choose the project you want to fund.
By becoming a member, you receive B-shares of the company, selecting from:
NG-VAD – Ventricular Assist Device – Patent US 10,722,628 B2
ARINAS – Surgical Software – Patent GB 2617559 A
Partner
The partner chosen by PulsaHeart LTD for the realization of its technologies in the medical-scientific field is Azzocor Research Center LTD. A specialized clinic that boasts a team of 21 internationally renowned professional such as Dr. prof. A. Pasqué and Dr. prof. P. Pantaleo
VAD
Among ius projects, PulsaHeart Fintech LTD propsed the research, development, testing, production, and sale of a VAD, Ventricular Assist Device
Research and trial
Optimization of Azzocor Research Centre’ knowledges in order to propose a tested and finished product to be industrialized bye one of the major player companies.
Deseas
This device could be implanted on subject waiting for transplant or as a temporary solution.
Industrialization
VAD device will be produced in Europe and assembled in Switzerland in order to guarantee the higest technological standard.
Patients
VAD device is suitable for adult and pediatric patient. Furthermore the operations has redused risks, a shorter duration and a quicker post-operation recovery.
1. NG - VAD – Ventricular Assist Device
- A next-generation implantable medical device designed to support patients suffering from severe heart failure.
- The global market is rapidly expanding, driven by increasing demand for life-saving technologies.
- An ideal opportunity for those who wish to support a tangible, patented product with significant clinical impact.
With your contribution, you will receive NG-VAD B-shares.
Current Stage
Having successfully passed the Bench Test in compliance with GLP standards, the project is now in the preclinical testing phase on animal models.
Following FDA approval, the next step will be to initiate clinical trials on humans, in accordance with approved regulatory protocols.
Key Advantages
A proven, patented medical solution
Suitable for both adult and pediatric patients
A physical device with high potential for industrial scalability
Aim
TECHNOLOGICAL
The animal testing is foresen to have a duration between 6 and 12 month.
At this stage the guinea pigs survive and later manage to return to their ordinary state of health.
Later, clinical trials will be done on humans in compliance with the FDA protocol.
financial
The distribution wil be managed by an American major player company, selected among the selector’ leaders.
The product will be promoted in the financial market through an STO, Security Token Offering.
The heart number
ARINAS
The second project developed by PulsaHeart LTD concerne a medical software capable of evaluating the patient’s situations without the need of surgery, but performing and ultrasound with A. I. optimization.
This procedure allows the surgeon to classify and understand which of the 22 medical-surgical procedures to perform.
2. ARINAS – Surgical Software
- An advanced AI-driven software designed to assist cardiac surgeons in the repair of heart valves.
- It enhances surgical precision, reduces operating time, and improves patient safety.
- An opportunity for those who want to support digital health innovation and the technological transformation of cardiac surgery.
With your contribution, you will receive ARINAS B-shares.
Current Stage
Building on the success achieved in mitral valve repair, the ARINAS project aims to develop an artificial intelligence (AI) algorithm capable of assisting cardiac surgeons in the diagnosis and surgical planning of all heart valve procedures.
The goal is to provide a reliable and precise tool that enhances clinical decision-making without replacing the role of the physician.
Key Advantages
Reduced operating time
Greater precision and patient safety during surgery
Broad applicability across multiple cardiac surgery procedures
The second project developed by PulsaHeart LTD concerne a medical software capable of evaluating the patient’s situations without the need of surgery, but performing and ultrasound with A. I. optimization.
This procedure allows the surgeon to classify and understand which of the 22 medical-surgical procedures to perform.
Our Patents
1
US 7,585,322 B2
- 08.09.2009
- PulsaHeart FinTech LTD
- 08.09.2009
- PulsaHeart FinTech LTD
- Inventor: G.Azzolina
- Assigne: ABM Heart Technologies LLC
- Cardiocirculatory aiding device
2
US 10,722,628 B2
- 28.06.2020
- PulsaHeart FinTech LTD
- 28.06.2020
- PulsaHeart FinTech LTD
- Inventor: G.Azzolina
- Assigne: Ellebi Fin LLC
- Cardiocirculatory aiding device
3
GB 2617559 A
- 18.10.2023
- PulsaHeart FinTech LTD
- 18.10.2023
- PulsaHeart FinTech LTD
- Computer-based method for
- planning surgery on a mitral
- valve
How It Works
Choose your project (NG-VAD or ARINAS) and the corresponding B-shares package.
Schedule a Discovery Call with one of our advisors to confirm your participation.
Become a member: receive your B-shares and gain access to exclusive project reports.
Member Benefits
Company shares proportional to your contribution
Regular updates on project development and roadmap progress
Exclusive access to confidential materials
Opportunity to diversify by investing in both projects
Comparison Between Opportunities
| Feature | NG-VAD – Ventricular Assist Device | ARINAS – Surgical Software |
|---|---|---|
| Description | An implantable mechanical device that assists the heart in pumping blood, designed for patients with advanced heart failure. It can be used as a bridge to transplant, as destination therapy, or as a recovery therapy. | AI-powered medical software that analyzes cardiac ultrasounds to guide cardiac surgeons in selecting the most appropriate valve repair procedures. |
| Type | Implantable medical device (mechanical) | Clinical software (digital health) |
| Clinical Impact | Improves blood flow, reduces symptoms, and extends life expectancy. Continuous improvements in technology (e.g., continuous-flow systems, increased durability). | Enhances surgical precision, shortens operating time, and improves clinical outcomes. Supports complex surgical decision-making. |
| Market | MedTech: life-saving devices with growing demand driven by advanced heart failure cases. | Digital Health: AI-assisted surgery, a rapidly expanding sector with strong interest from hospitals and healthcare systems. |
| Development Stage | Preclinical phase, optimization and testing in collaboration with partners such as Azzocor Research Center. | Software development in progress, with upcoming clinical validation phases. |
| Key Advantages | Tangible, industrializable solution in Europe/Switzerland; applicable to both adult and pediatric patients. | Scalable, innovative technology — easily upgradable and applicable across a wide range of cardiac surgery procedures. |
| Available B-shares | NG-VAD B-shares | ARINAS B-shares |
NG-VAD - Next Generation Ventricular Assist Device
The NG-VAD is an implantable mechanical device designed to support or replace ventricular function in patients with severe heart failure.
In less advanced cases, the device can promote recovery of cardiac function, potentially leading to complete healing.
It can be used as a bridge to transplant or as a destination therapy when transplantation is not possible, with applications in both adult and pediatric patients.
Next-generation devices — particularly pulsatile-flow systems — ensure greater durability, safety, and comfort, significantly improving both quality of life and life expectancy.
Technological Objective
- The animal testing phase is expected to last 6–12 months.
- During this stage, the test subjects survive and subsequently return to their normal state of health.
- Following this phase, clinical trials on humans will be conducted in full compliance with FDA regulatory protocols.
ARINAS – Artificial Intelligence Assistance
ARINAS is an advanced artificial intelligence software designed to:
Analyze echocardiographic images
Assist cardiac surgeons in selecting the most appropriate procedures for heart valve reconstruction
The system enhances diagnostic accuracy, reduces surgical time, and improves clinical outcomes, positioning itself as a scalable solution driving the digital transformation of cardiology.
PulsaHeart Fintech LTD – London, United Kingdom
With over five years of experience in the medical biotechnology sector, we specialize in developing innovative solutions that combine biomedical engineering and digital health to improve the lives of patients with heart disease.
We collaborate with Azzocor Research Center Ltd, a multidisciplinary team of 21 engineers and physicians led by Prof. Paolo Pantaleo, an internationally recognized expert in the field.
Our projects are supported by registered patents and rigorous scientific protocols, conducted in full compliance with FDA and GLP standards to ensure the highest quality and reliability of results.
Our Values
- Scientific Rigor – All our projects adhere to the highest standards of international research and regulatory compliance.
- Continuous Innovation – Azzocor is constantly engaged in developing new technologies and collaborating with leading research centers worldwide.
- Multidisciplinary Approach – Our team brings together diverse expertise, addressing cardiovascular challenges from every perspective.
Limited Opportunity
This initial phase is reserved for a select group of qualified members.
Would you like to join our mission and choose which technology to support?
Request Your Membership Call
NEWS
In December 2022
Johnson & Johnson MedTech acquired Abiomed for USD 16.6 billion, the owner...
In November 2023
Johnson & Johnson MedTech acquired Laminar Inc. for USD 400 million.
In April 2024
Johnson & Johnson MedTech acquired Shockwave Medical for USD 13.1 billion.
In August 2024
Johnson & Johnson MedTech acquired V-Ware for USD 600 million, and—with FDA ...